Aastrom Shows Off Vascular Results
Luke Timmerman6/11/10
Aastrom Biosciences, the Ann Arbor, MI-based developer of cell therapies for cardiovascular diseases, is presenting some new data on a clinical trial of its method against critical limb ischemia, a complication of clogged arteries that often leads to amputation and death. Detailed results from half of the first 90 patients are being presented today at the Society of Vascular Surgery meeting in Boston. Aastrom (NASDAQ: ASTM) is hosting a conference call to discuss the results today at 3:30 pm Eastern time. We profiled the company earlier this month.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
